Studies of the Prevention of Atrial Fibrillation by ALA
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00410839|
Recruitment Status : Unknown
Verified August 2004 by University of Toronto.
Recruitment status was: Active, not recruiting
First Posted : December 13, 2006
Last Update Posted : December 13, 2006
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation Diet Therapy||Procedure: ALA rich diet||Phase 2|
Objective: We determined the effect of an ALA rich diet in reducing recurrence of atrial fibrillation as a further example of a cardiac arrhythmia.
Design: Randomized parallel design efficacy study. Setting: Three university hospital centers in the Bordeaux region, France. Patients: 98 successive patients successfully underwent electro cardioversion of whom 75 completed the study without major deviations according to the protocol.
Intervention: A canola margarine and oil together with a Mediterranean diet (ALA ω-3, 1.4 g/d) versus a conventional diet (control), with a one year follow-up.
Main outcome measure: Length of time to first recurrence of atrial fibrillation.
Significance: If ALA is antiarrhythmic this action may explain its cardioprotective effect in clinical trials and cohort studies.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||130 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prevention of Atrial Fibrillation Recurrence By An Alpha-Linolenic Enriched Diet - A Pilot Study|
|Study Start Date :||June 1999|
|Estimated Study Completion Date :||June 2003|
- rate of recurrence and length of time to first recurrence of atrial fibrillation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00410839
|Emile Roux Hospital|
|Paris, France, 94456|
|Principal Investigator:||Serge Renaud, MD, PhD||Emile Roux Hospital, A.P.H. Paris, 94456 Limeil-Brevannes, France|